Dato-DXd May Change First-Line Treatment for Triple-Negative Breast Cancer When Immunotherapy Is Not an Option
There is important news for patients with triple-negative breast cancer (TNBC). In Europe, the regulatory procedure continues for expanding the indication for Dato-DXd (datopotamab deruxtecan), a TROP2-directed antibody-drug conjugate. In the United States, the FDA has accepted a Priority Review application for the use of Dato-DXd as first-line treatment in adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 checkpoint inhibitor therapy.
This is a significant development for a group of patients who have historically had very limited options. When immunotherapy is not suitable — whether due to low PD-L1 expression, contraindications, or other clinical factors — standard chemotherapy has remained the default. Now there is a real possibility for a more effective alternative.
TROPION-Breast02: Study Results
The basis for this regulatory submission is the TROPION-Breast02 study, a phase III randomized trial that compared Dato-DXd with investigator’s choice chemotherapy in patients with previously untreated unresectable or metastatic TNBC who were not eligible for treatment with PD-1/PD-L1 inhibitors.
Dato-DXd improved median overall survival (OS) to 23.7 months compared with 18.7 months on chemotherapy (HR 0.79). For progression-free survival (PFS), the difference was even more pronounced: 10.8 months versus 5.6 months (HR 0.57). This means Dato-DXd nearly doubled the time before disease progression.
Why This Matters
This is the first therapy in this specific patient group — first-line TNBC when immunotherapy is not an option — to demonstrate improvements in both PFS and OS compared with standard chemotherapy. Until now, there has been no drug that could do both in this setting. That is why these results are generating such interest among the oncology community.
Regulatory Status
Dato-DXd is already approved in Russia, but for different indications: EGFR-mutated non-small cell lung cancer (NSCLC) and HR-positive, HER2-negative breast cancer. The first-line TNBC indication is not yet registered anywhere, but the regulatory process is actively underway in both the EU (where the PRAC is reviewing the application) and the US (where the FDA has granted Priority Review).
This means the current news is about a potential new indication, not a new drug as such. The drug is already known and used, but the expansion to TNBC would be a meaningful addition to the treatment landscape.
When to Seek a Second Opinion
A consultation may be particularly valuable if:
- you have been diagnosed with triple-negative breast cancer and are starting or considering first-line treatment
- immunotherapy has been ruled out for you, and you want to understand what other options exist
- you are unsure whether your PD-L1 status has been assessed correctly or completely
- doctors’ opinions differ on the optimal treatment plan
- you want to understand how closely your current plan aligns with the latest clinical trial data
What to Prepare Before Your Consultation
For a thorough review, it is helpful to have the following ready:
- histopathology report with immunohistochemistry (IHC) results, including ER, PR, HER2, Ki-67
- PD-L1 testing results (CPS score), if available
- CT, MRI, or PET-CT scans with dates
- a summary of any prior treatment, including neoadjuvant therapy if applicable
- discharge summaries and treatment records
- information about tolerability of any previous treatment
Conclusion
The TROPION-Breast02 data represent a meaningful step forward for patients with triple-negative breast cancer who cannot receive immunotherapy. Dato-DXd (datopotamab deruxtecan) has shown improvements in both overall survival and progression-free survival over standard chemotherapy in this setting — something no other drug has achieved before in this specific group. While the regulatory process is still underway, these results are already influencing how oncologists think about first-line treatment options for TNBC.
Frequently Asked Questions
What is Dato-DXd (datopotamab deruxtecan)?
Dato-DXd is a TROP2-directed antibody-drug conjugate (ADC). The antibody binds to the TROP2 protein on the surface of tumor cells, delivering deruxtecan, a topoisomerase I inhibitor, directly into the cancer cell. This is a targeted delivery mechanism for the cytotoxic payload.
What did the TROPION-Breast02 study show?
Dato-DXd improved median overall survival to 23.7 months versus 18.7 months with chemotherapy (HR 0.79). Median progression-free survival was 10.8 months versus 5.6 months (HR 0.57). This is the first therapy in this patient group to demonstrate improvements in both PFS and OS over standard chemotherapy.
Who is eligible for Dato-DXd under this new indication?
The expanded indication being pursued covers adults with unresectable or metastatic triple-negative breast cancer who are not eligible for treatment with PD-1/PD-L1 checkpoint inhibitors. This is an important group of patients who previously had limited options beyond standard chemotherapy.
Is Dato-DXd available in Russia?
Yes, Dato-DXd is already registered in Russia, but for other indications: EGFR-mutated non-small cell lung cancer and HR-positive, HER2-negative breast cancer. The first-line TNBC indication is not yet approved, but the regulatory process is underway in the EU and US.
Should I switch my treatment to Dato-DXd on my own?
No. Treatment decisions must always be made together with your oncologist. A thorough review of your histopathology, immunohistochemistry results, PD-L1 status, prior treatment, and overall clinical picture is essential. A second opinion consultation can help you understand your options.
More answers on the FAQ page.